OPTI — OptiBiotix Health Share Price
Last trade - 00:00- £10.59m
- £9.85m
- £0.87m
- 36
- 16
- 18
- 10
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.26 | ||
| Price to Tang. Book | 1.45 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 12.17 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -26.12% | ||
| Return on Equity | -20.9% | ||
| Operating Margin | -260.46% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 1.52 | 2.21 | 0.46 | 0.64 | 0.87 | n/a | n/a | 3.15% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +102.32 | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
OptiBiotix Health Plc is a life sciences company. The Company is engaged in the development of microbial strains, compounds, and formulations, which are used as active ingredients and supplements. It is focused on the development of products which reduce hunger and food cravings, enhance the gut microbiome, and provide a healthy substitute for sugar. It is also developing its own range of consumer supplements and health products. Its areas of focus include obesity, cardiovascular health, and diabetes. Its products include SlimBiome, CholBiome, SweetBiotix, WellBiome, OptiBiotics and SlimBiome X3. SlimBiome offers a natural, scientifically supported, non-pharmaceutical approach to reducing hunger and cravings. CholBiome contains Lactobacillus plantarum LPLDL as the only active ingredient, focusing on healthy cholesterol maintenance and delivering tangible health benefits. SweetBiotix is a zero or low-calorie, prebiotic, and a smarter alternative to sugar and existing sweeteners.
Directors
- Richard Davidson NEC
- Stephen O'hara CEO
- Sofia Kolyda EDR
- Taru Jainas OTH
- Mikkel Hvid-Hansen DRC (53)
- Christopher Brinsmead NED (62)
- Michael Christie NID (64)
- Stephen Hammond NID (59)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 19th, 2006
- Public Since
- September 9th, 2011
- No. of Employees
- 5
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 103,300,304
- Address
- Innovation Centre, HESLINGTON, Y010 5DG
- Web
- http://www.optibiotix.com
- Phone
- +44 2079338780
- Auditors
- Gerald Edelman
Latest News for OPTI
Upcoming Events for OPTI
Half Year 2025 OptiBiotix Health PLC Earnings Release
OptiBiotix Health PLC Annual Shareholders Meeting
Similar to OPTI
4Basebio
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
Bioventix
London Stock Exchange
FAQ
As of Today at 22:26 UTC, shares in OptiBiotix Health are trading at 10.25p. This share price information is delayed by 15 minutes.
Shares in OptiBiotix Health last closed at 10.25p and the price had moved by -46.75% over the past 365 days. In terms of relative price strength the OptiBiotix Health share price has underperformed the FTSE All Share Index by -52.01% over the past year.
The overall consensus recommendation for OptiBiotix Health is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreOptiBiotix Health does not currently pay a dividend.
OptiBiotix Health does not currently pay a dividend.
OptiBiotix Health does not currently pay a dividend.
To buy shares in OptiBiotix Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 10.25p, shares in OptiBiotix Health had a market capitalisation of £10.59m.
Here are the trading details for OptiBiotix Health:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: OPTI
Based on an overall assessment of its quality, value and momentum OptiBiotix Health is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in OptiBiotix Health is 93.00p. That is 807.32% above the last closing price of 10.25p.
Analysts covering OptiBiotix Health currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like OptiBiotix Health. Over the past six months, its share price has underperformed the FTSE All Share Index by -44.52%.
As of the last closing price of 10.25p, shares in OptiBiotix Health were trading -32.77% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The OptiBiotix Health PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 10.25p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
OptiBiotix Health's management team is headed by:
- Richard Davidson - NEC
- Stephen O'hara - CEO
- Sofia Kolyda - EDR
- Taru Jainas - OTH
- Mikkel Hvid-Hansen - DRC
- Christopher Brinsmead - NED
- Michael Christie - NID
- Stephen Hammond - NID